期刊
ANNALS OF THE RHEUMATIC DISEASES
卷 81, 期 5, 页码 653-661出版社
BMJ PUBLISHING GROUP
DOI: 10.1136/annrheumdis-2021-221865
关键词
-
类别
资金
- Kiniksa Pharmaceuticals
- Ministerio de Ciencia e Innovacion [SAF 2017/88275-R, PID2020-114909RB-I00]
- Fondo Europeo de Desarrollo Regional (FEDER)
- CERCA programme
- National Health and Medical Research Council of Australia [1154325, 1113577]
- Reid Charitable Trusts
This study evaluated the efficacy of the GM-CSF receptor antagonist mavrilimumab in maintaining disease remission in patients with giant cell arteritis. The results showed that mavrilimumab plus prednisone was superior to placebo plus prednisone in terms of time to flare and sustained remission.
Objectives Granulocyte-macrophage colony- stimulating factor (GM-CSF) is implicated in pathogenesis of giant cell arteritis. We evaluated the efficacy of the GM-CSF receptor antagonist mavrilimumab in maintaining disease remission. Methods This phase 2, double-blind, placebo-controlled trial enrolled patients with biopsy-confirmed or imaging-confirmed giant cell arteritis in 50 centres (North America, Europe, Australia). Active disease within 6 weeks of baseline was required for inclusion. Patients in glucocorticoid-induced remission were randomly assigned (3:2 ratio) to mavrilimumab 150 mg or placebo injected subcutaneously every 2 weeks. Both groups received a 26-week prednisone taper. The primary outcome was time to adjudicated flare by week 26. A prespecified secondary efficacy outcome was sustained remission at week 26 by Kaplan-Meier estimation. Safety was also assessed. Results Of 42 mavrilimumab recipients, flare occurred in 19% (n=8). Of 28 placebo recipients, flare occurred in 46% (n=13). Median time to flare (primary outcome) was 25.1 weeks in the placebo group, but the median was not reached in the mavrilimumab group (HR 0.38; 95% CI 0.15 to 0.92; p=0.026). Sustained remission at week 26 was 83% for mavrilimumab and 50% for placebo recipients (p=0.0038). Adverse events occurred in 78.6% (n=33) of mavrilimumab and 89.3% (n=25) of placebo recipients. No deaths or vision loss occurred in either group. Conclusions Mavrilimumab plus 26 weeks of prednisone was superior to placebo plus 26 weeks of prednisone for time to flare by week 26 and sustained remission in patients with giant cell arteritis. Longer treatment is needed to determine response durability and quantify the glucocorticoid-sparing potential of mavrilimumab.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据